{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:25:26Z","timestamp":1765545926372},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107424","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T18:12:20Z","timestamp":1411063940000},"page":"e107424","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00515216","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Laura W.","family":"Goff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana B.","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan D.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zehnbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1055-3207(02)00002-9","article-title":"Epidemiologic trends in esophageal and gastric cancer in the United States","volume":"11","author":"LM Brown","year":"2002","journal-title":"Surg Oncol Clin N Am"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.11029","article-title":"Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas","volume":"105","author":"AP Polednak","year":"2003","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"D Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"YJ Bang","year":"2010","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"E Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-8-148","article-title":"Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker","volume":"8","author":"B Keam","year":"2008","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/02841860600791483","article-title":"A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer","volume":"46","author":"SY Oh","year":"2007","journal-title":"Acta Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6602573","article-title":"A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients","volume":"92","author":"F De Vita","year":"2005","journal-title":"Br J Cancer"},{"key":"ref9","unstructured":"Chu E, Moto AC, Fogarasi MC (2001) Cancer: Principles &amp; Practice of Oncology; De Vita JVT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott Williams &amp; Wilkins. 388\u2013415 p."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3816\/CCC.2001.n.018","article-title":"Thymidylate synthase pharmacogenetics in colorectal cancer. [see comment]","volume":"1","author":"S Marsh","year":"2001","journal-title":"Clin Colorectal Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1247\/csf.20.191","article-title":"Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase","volume":"20","author":"N Horie","year":"1995","journal-title":"Cell Struct Funct"},{"key":"ref12","first-page":"3249","article-title":"Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers","volume":"19","author":"K Kawakami","year":"1999","journal-title":"Anticancer Res"},{"key":"ref13","first-page":"1381","article-title":"Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene","volume":"9","author":"CM Ulrich","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref14","first-page":"4096","article-title":"Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression","volume":"7","author":"K Kawakami","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/geno.1999.5833","article-title":"Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations","volume":"58","author":"S Marsh","year":"1999","journal-title":"Genomics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1054\/bjoc.2001.2007","article-title":"A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil","volume":"85","author":"B Iacopetta","year":"2001","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","article-title":"Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy","volume":"1","author":"ST Pullarkat","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.2001.19.6.1779","article-title":"Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer","volume":"19","author":"E Villafranca","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"R Metzger","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8","article-title":"High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy","volume":"82","author":"KH Yeh","year":"1998","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1200\/JCO.2010.32.3212","article-title":"Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma","volume":"29","author":"BR Tan","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3892\/or_00000584","article-title":"Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study","volume":"22","author":"LA Henriquez-Hernandez","year":"2009","journal-title":"Oncol Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.22568","article-title":"Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele","volume":"120","author":"LF Lincz","year":"2007","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e3283415124","article-title":"Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy","volume":"21","author":"MY Huang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-8-50","article-title":"ERCC2 2251A&gt;C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study","volume":"8","author":"MY Huang","year":"2008","journal-title":"BMC Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1756-0500-5-263","article-title":"XRCC1 Arg399Gln was associated with repair capacity for DNA damage induced by occupational chromium exposure","volume":"5","author":"XH Zhang","year":"2012","journal-title":"BMC Res Notes"},{"key":"ref27","first-page":"2557","article-title":"XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency","volume":"59","author":"RM Lunn","year":"1999","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1158\/1055-9965.EPI-05-0143","article-title":"Genetic polymorphisms in XRCC1, APE1, ADPRT, XRCC2, and XRCC3 and risk of chronic benzene poisoning in a Chinese occupational population","volume":"14","author":"Z Zhang","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref29","first-page":"2898","article-title":"A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity","volume":"63","author":"MV Mandola","year":"2003","journal-title":"Cancer Res"},{"key":"ref30","first-page":"6004","article-title":"Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene","volume":"63","author":"K Kawakami","year":"2003","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"R Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/COC.0b013e31820dc0b0","article-title":"Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer","volume":"35","author":"J Ocvirk","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00280-010-1295-z","article-title":"Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design","volume":"66","author":"YW Moon","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdq591","article-title":"Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study","volume":"22","author":"M Moehler","year":"2011","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/annonc\/mdp464","article-title":"Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)","volume":"21","author":"W Koizumi","year":"2010","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000330199","article-title":"Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer","volume":"80","author":"K Amarantidis","year":"2011","journal-title":"Oncology"},{"key":"ref37","first-page":"1378","article-title":"Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer","volume":"6","author":"D Edler","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","article-title":"Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis","volume":"22","author":"S Popat","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/ijc.22235","article-title":"The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer","volume":"119","author":"K Ott","year":"2006","journal-title":"Int J Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1158\/1078-0432.CCR-04-2428","article-title":"Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy","volume":"11","author":"K Kawakami","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.coc.0000256059.88247.25","article-title":"Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II\/III esophageal squamous cell carcinoma in Japanese","volume":"30","author":"T Okuno","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.bjc.6602697","article-title":"Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer","volume":"93","author":"F Lordick","year":"2005","journal-title":"Br J Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6601985","article-title":"Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer","volume":"91","author":"Y Chao","year":"2004","journal-title":"Br J Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"ML Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00001813-200404000-00010","article-title":"Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells","volume":"15","author":"KH Yeh","year":"2004","journal-title":"Anticancer Drugs"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.bjc.6603866","article-title":"Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil","volume":"97","author":"CC Chen","year":"2007","journal-title":"Br J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2010.835","article-title":"Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase","volume":"24","author":"M Fukushima","year":"2010","journal-title":"Oncol Rep"},{"key":"ref48","first-page":"2083","article-title":"Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells","volume":"29","author":"S Torigoe","year":"2009","journal-title":"Anticancer Res"},{"key":"ref49","first-page":"2455","article-title":"Thymidylate synthetase (TS) genotype and TS\/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma","volume":"24","author":"F Toriumi","year":"2004","journal-title":"Anticancer Res"},{"key":"ref50","first-page":"2405","article-title":"MDR1 gene C3435 T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy","volume":"12","author":"Y Li","year":"2011","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T08:13:48Z","timestamp":1540023228000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107424"}},"subtitle":[],"editor":[{"given":"Keitaro","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107424","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}